Clinical Trial: NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Regeneron Pharmaceuticals |
| Information Provided By: | Regeneron Pharmaceuticals |
| Last Update Posted: | 2025-10-10 |
Study Overview
Brief Summary
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.
Official Title
Conditions
Intervention / Treatment
- Drug: Odronextamab multiple dose levels
- Drug: Odronextamab multiple dose levels
Other Study ID Numbers
- R1979-HM-1333
- 2015-004491-30
- 2024-514938-20-00
- 2015
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Regeneron Pharmaceuticals |
| Information Provided By: | Regeneron Pharmaceuticals |
| Last Update Posted: | 2025-10-10 |
Study Overview
Brief Summary
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.
Official Title
Conditions
Intervention / Treatment
- Drug: Odronextamab multiple dose levels
- Drug: Odronextamab multiple dose levels
Other Study ID Numbers
- R1979-HM-1333
- 2015-004491-30
- 2024-514938-20-00
- 2015